190 related articles for article (PubMed ID: 27339942)
1. Immune signaling-based Cascade Propagation approach re-stratifies HNSCC patients.
Liu K; Chyr J; Zhao W; Zhou X
Methods; 2016 Dec; 111():72-79. PubMed ID: 27339942
[TBL] [Abstract][Full Text] [Related]
2. Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.
Bates AM; Lanzel EA; Qian F; Abbasi T; Vali S; Brogden KA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Aug; 124(2):157-164. PubMed ID: 28756882
[TBL] [Abstract][Full Text] [Related]
3. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
4. Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.
Secrier M; McGrath L; Ng F; Gulati S; Raymond A; Nuttall BRB; Berthe J; Jones EV; Sidders BS; Galon J; Barrett JC; Angell HK
Cancer Res Commun; 2023 Oct; 3(10):2133-2145. PubMed ID: 37819239
[TBL] [Abstract][Full Text] [Related]
5. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data.
De Cecco L; Nicolau M; Giannoccaro M; Daidone MG; Bossi P; Locati L; Licitra L; Canevari S
Oncotarget; 2015 Apr; 6(11):9627-42. PubMed ID: 25821127
[TBL] [Abstract][Full Text] [Related]
6. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
7. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
8. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells.
Summerer I; Hess J; Pitea A; Unger K; Hieber L; Selmansberger M; Lauber K; Zitzelsberger H
BMC Genomics; 2015 Sep; 16(1):654. PubMed ID: 26328888
[TBL] [Abstract][Full Text] [Related]
10. Integrating genomics in head and neck cancer treatment: Promises and pitfalls.
Thariat J; Vignot S; Lapierre A; Falk AT; Guigay J; Van Obberghen-Schilling E; Milano G
Crit Rev Oncol Hematol; 2015 Sep; 95(3):397-406. PubMed ID: 25979769
[TBL] [Abstract][Full Text] [Related]
11. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Al-Amri AM; Vatte C; Cyrus C; Chathoth S; Hashim TM; Mohamed YS; Al Ali R; Alsaid A; Al Ali A
Cancer Biomark; 2016; 16(3):377-83. PubMed ID: 26889984
[TBL] [Abstract][Full Text] [Related]
12. Subpath analysis of each subtype of head and neck cancer based on the regulatory relationship between miRNAs and biological pathways.
An F; Zhang Z; Xia M; Xing L
Oncol Rep; 2015 Oct; 34(4):1745-54. PubMed ID: 26239836
[TBL] [Abstract][Full Text] [Related]
13. HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients.
Wichmann G; Herchenhahn C; Boehm A; Mozet C; Hofer M; Fischer M; Kolb M; Dietz A
Oral Oncol; 2017 Jun; 69():115-127. PubMed ID: 28559015
[TBL] [Abstract][Full Text] [Related]
14. Predicting miRNA targets for head and neck squamous cell carcinoma using an ensemble method.
Gao H; Jin H; Li G
Int J Biol Markers; 2018 Jan; 33(1):87-93. PubMed ID: 28665450
[TBL] [Abstract][Full Text] [Related]
15. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
[TBL] [Abstract][Full Text] [Related]
16. Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC.
Gaykalova DA; Zizkova V; Guo T; Tiscareno I; Wei Y; Vatapalli R; Hennessey PT; Ahn J; Danilova L; Khan Z; Bishop JA; Gutkind JS; Koch WM; Westra WH; Fertig EJ; Ochs MF; Califano JA
Oncotarget; 2017 Feb; 8(9):15349-15363. PubMed ID: 28146432
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?
Tonella L; Giannoccaro M; Alfieri S; Canevari S; De Cecco L
Curr Treat Options Oncol; 2017 May; 18(5):32. PubMed ID: 28474265
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
19. Clusterization in head and neck squamous carcinomas based on lncRNA expression: molecular and clinical correlates.
de Lena PG; Paz-Gallardo A; Paramio JM; García-Escudero R
Clin Epigenetics; 2017; 9():36. PubMed ID: 28405244
[TBL] [Abstract][Full Text] [Related]
20. Novel insights into head and neck cancer using next-generation "omic" technologies.
Sepiashvili L; Bruce JP; Huang SH; O'Sullivan B; Liu FF; Kislinger T
Cancer Res; 2015 Feb; 75(3):480-6. PubMed ID: 25589349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
